|Year : 2023 | Volume
| Issue : 1 | Page : 51-55
Bioassay for total serum bioactivity of Atractylodes lancea
Kesara Na-Bangchang, Anurak Cheoymang, Nadda Muhamad, Inthuon Kulma
Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumthani, Thailand
|Date of Submission||07-Jun-2022|
|Date of Decision||09-Aug-2022|
|Date of Acceptance||27-Sep-2022|
|Date of Web Publication||20-Jan-2023|
Prof. Kesara Na-Bangchang
Chulabhorn International College of Medicine, Thammasat University, 99 Moo 18, Paholyothin Road, Klong Luang, Pathumtanee
Source of Support: None, Conflict of Interest: None
The study aimed to establish a bioassay for total bioactivity of Atractylodes lancea (AL) in human serum samples. Inhibition of bacterial growth (Staphylococcus aureus ATCC 25923) was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The calibration curve (0, 0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/ml) was linear with correlation coefficients >0.990. The limit of quantification (LOQ) was 1.66 mg/ml using 20-ml serum sample. The developed bioassay method meets the standard of the bioanalytical method for determination of serum bioactivity of AL.
Keywords: Atractylodes lancea, atractylodin, bioassay, cholangiocarcinoma, pharmacokinetics, Staphylococcus aureus ATCC 25923
|How to cite this article:|
Na-Bangchang K, Cheoymang A, Muhamad N, Kulma I. Bioassay for total serum bioactivity of Atractylodes lancea. J Adv Pharm Technol Res 2023;14:51-5
|How to cite this URL:|
Na-Bangchang K, Cheoymang A, Muhamad N, Kulma I. Bioassay for total serum bioactivity of Atractylodes lancea. J Adv Pharm Technol Res [serial online] 2023 [cited 2023 Feb 4];14:51-5. Available from: https://www.japtr.org/text.asp?2023/14/1/51/368243
| Introduction|| |
Atractylodes lancea (AL) is used in China, Japan, and Thailand for treatment of rheumatic diseases, digestive disorders, night blindness, influenza, fever, cold, etc.,, These ethnopharmacological uses are supported by the wide range of pharmacological activities of AL in various diseases., A series of studies conducted by our group confirms the potential of AL as a chemotherapeutic for cholangiocarcinoma (bile duct cancer).,,
Bioanalysis of AL is challenging due to its complexity and large number of constituents. Gas chromatography, high-performance liquid chromatography, liquid chromatography-mass spectrometry, and ultra-performance liquid chromatography coupled with electrospray ionization LTQ-Orbitrap high-resolution mass spectrometry have been widely employed for the identification and quantitation of the two main bioactive compounds, atractylodin and b-eudesmol.,,,,,, As several components may contribute to each AL pharmacological activity, it is likely that bioanalysis and investigation of the concentration–time profile (pharmacokinetic study) of a single constituent by these methods may not be correlated well with the overall pharmacodynamic activity of AL. Bioassay which measures total activity of all constituents, however, would better reflect the sum of bioactivity of all components in the herbal extract. The present study aimed to establish a high-throughput bioassay for measurement of the total bioactivity of AL against cholangiocarcinoma cells in human serum samples compared to the high-performance liquid chromatography-ultraviolet (HPLC-UV) method. The pharmacokinetic study of AL was successfully characterized in Thai patients with advanced stage cholangiocarcinoma using the developed method.
| Materials and Methods|| |
Atractylodin was provided by Shanghai Run-Biotech Co., Ltd. HPLC-grade reagents were provided by Fisher Scientific. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and other chemicals were provided by Sigma Chemical Co.
Bioassay for measurement of serum ATD
Preparation of bacterial suspension
Biochemical identification of Staphylococcus aureus ATCC 25923 strain was performed using the previously described method. Blood agar (Difco Labo.) and LB broth (Difco Lab.) were used to isolate bacterial colonies (37°C, 18–20 h). The colonies were suspended to the turbidity of the 0.5 McFarland standard to achieve the density of 1 × 104 colony-forming unit (CFU)/ml.
Preparation of drug solutions
Atractylodin (ATD) stock solution of 1,000 ng/μl was prepared in dimethyl sulfoxide and two-fold serially diluted with human blank serum (heat-activated) to prepare working solutions (0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/μl).
Serum samples were heat-activated at 60°C to remove microbial contamination. Serum (20 μl) containing ATD (0, 0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/μl; triplicate each) was pipetted into each well of the 96-well microtiter plate (Thermo Fisher Scientific Instruments Co., Suzhou, Jiangsu, China) containing bacterial suspension (150 μl, 1 × 104 CFU per μl) in LB broth and cultured in an incubator (37°C, 18–24 h).
Assessment of Staphylococcus aureus growth
Each microtiter plate well was added with the MTT solution (10 μl of 5 mg/ml) and left at 25°C for 5 min. Optical density (OD) was read at 570 nm. Bacterial growth (%) was determined as the ratio of the OD of drug-treated wells/OD of control wells. The calibration curve (x-axis: log ATD concentration vs. y-axis: % bacteria growth) vs. the x-axis (log ATD concentration) was prepared and analyzed by nonlinear regression (CalcuSynTM, Biosoft, Cambridge, UK).
The total serum bioactivity of AL against S. aureus was determined from the calibration curve and expressed as ATD equivalent concentration (ATDeq-Sa). The total serum bioactivity of AL against cholangiocarcinoma cells was obtained by multiplying the ATDeq-Sa with the IC50 ratio of AL in cholangiocarcinoma and S. aureus (multiplying factor) and expressed as ATDeq-cca. The average IC50 (50% inhibitory concentration) of the AL extract in various cholangiocarcinoma cell lines is 30 μg/ml. The IC50 of AL crude extract for S. aureus determined in the present study is 11.42 μg/ml. Therefore, the multiplying factor used to determine the total bioactivity of AL against cholangiocarcinoma cells is 30/11.42 = 2.63.
Calibration curves for serum samples were prepared by spiking with ATD (0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/μl).
The within-day precision of the assay was evaluated by the analysis of serum samples (20 μl each) spiked with ATD at 0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/μl (n = 6 each). The day-to-day precision was determined using the same concentration range, but on 6 consecutive days. The coefficient of variation (%CV) was calculated from the ratio of standard deviation (SD) and mean and multiplied by 100.
The accuracy was evaluated by the analysis of six sets of samples spiked with ATD at 0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/μl (n = 6 each). The difference between spiked concentrations and concentrations added is expressed as % mean deviation (%MDV).
The quantification limit (LOQ) of the assay was determined from the lowest ATD concentration that inhibited bacterial growth.
High-performance liquid chromatography-ultraviolet analysis of plasma ATD
The standard HPLC-UV method was used to determine plasma ATD concentrations. Plasma sample was precipitated with acetonitrile and extracted with dichloromethane. The system consisted of the solvent pump, solvent degasser, autosampler, UV detector at the wavelength of 340 nm (Thermo Fisher Scientific, CA, USA), reversed-phase column (Thermo Hypersil Gold C18, 5 μm), mobile phase (acetonitrile (70%): distilled water (30%), 1.0 ml/min), and Millennium 2000 Chromatograph™ software (Waters Co. Ltd.). All calibration curves (2.5–500 ng/ml) yielded a linear relationship with r > 0.999. The %CV of ATD analysis was below 5% at all concentrations (25, 100, and 500 ng/ml). %CV for the intraday and interday assay precision varied between 0.9% to 2.9% and 2.2% to 3.3%, respectively. The MDV values for the intraday and interday assay accuracy varied between 0.2% to 6.1% and 2.9% to 7.0%, respectively. The mean (+SD) recovery of ATD was 76.2%. The LOQ of ATD was 2.5 ng/ml. Plasma samples containing ATD (25, 100, and 500 ng/ml) were found to be stable at −80°C, and three cycles of freeze and thaw procedures.
Application of bioassay for pharmacokinetic study
The pharmacokinetic study of the total serum bioactivity (anticholangiocarcinoma) of AL (ATDeq-cca) was conducted in five Thai patients with advanced stage cholangiocarcinoma (48–62 years of age, 50–65 kg), who received treatment with oral dose of 1,000 mg AL extract (Kao Laoor Co. Ltd., Thailand). Plasma concentrations of ATD in plasma were determined by HPLC-UV. The Ethics Committee of Thammasat University approved the study protocol. Participants gave written informed consents before the study. Venous blood (6 ml) was collected (3 ml into the heparinized tube and 3 ml into the plain tube) at the following time points: 0 (before dose) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after dosing. Plasma (for ATD analysis) and serum (for analysis of the total bioactivity) samples were separated (centrifugation at 2,000×g for 15 min) and stored at −20°C.
| Results and Discussion|| |
Bioassay for determination of total bioactivity of AL in serum samples
All calibration curves (0.39-50 ng/μl ATD) yielded linear relationship with correlation coefficients >0.990 [Figure 1]. The variation of ATDeq-cca assay in serum samples was low, with %CV below 15% at the three concentrations (0.78, 6.50, and 25.00 μg/ml). The assay provided a good intra- and interday precision (%CV: 6.49%–14.63%) and intra- and interday accuracy (MDV: −3.01–+10.55%) [Table 1]. The LOQ of the assay was 1.66 μg/ml using 20-μl serum sample.
|Figure 1: Calibration curve (0.39-50 μg/ml) of the total bioactivity of AL in serum against Staphylococcus aureus (expressed as ATDeq-cca)|
Click here to view
|Table 1: Assay precision and accuracy (percentage DMV) for the total serum bioactivity of Atractylodes lancea determined by bioassay (atractylodin equivalent concentration)|
Click here to view
Application of the bioassay method for human pharmacokinetic study
The ATDeq-cca concentrations representing total anticholangiocarcinoma activity of AL in serum samples from the five patients are presented in [Table 2]. The average maximum serum bioactivity of 16.54 ATDeq-cca concentration was achieved at 0.5 h. At the last sampling time point (6 h), ATDeq-cca was not detectable in two patients, while low activity (2.63–9.70 ATDeq-cca) was detected in three patients.
|Table 2: Serum total bioactivity (anticholangiocarcinoma activity) of Atractylodes lancea extract expressed as atractylodin equivalent concentration|
Click here to view
ATD concentrations at various time points in the five patients are presented in [Table 3]. The average maximum plasma concentration of ATD of 65.90 ng/ml was achieved at 2.5 h. At the last sampling time point (6 h), ATD was not detectable in two patients, while low concentrations (5.20-14.95 ng/ml) were detected in three patients. Comparison of serum bioactivity expressed as ATDeq-cca and plasma ATD concentrations in all patients is presented in [Figure 2]. It was noted a marked difference in the pharmacokinetic profiles of AL when using ATD and ATDeq-cca as biomarkers for anticholangiocarcinoma.
|Figure 2: The mean serum AL bioactivity (expressed as ATDeq-cca) and plasma ATD concentrations in five patients with advanced stage cholangiocarcinoma|
Click here to view
|Table 3: Plasma concentrations of atractylodin analyzed by high-performance liquid chromatography-ultraviolet|
Click here to view
| Conclusions|| |
A bioassay based on the colorimetric analysis of the total bioactivity of AL against cholangiocarcinoma in human serum fulfills the criteria of analytical assay performance., The assay results reflect the sum of the activity of all identified and unidentified active constituents. The end point of measurement was bacterial growth inhibition assessed by MTT assay, which provides a high-throughput platform for the assay. This would offer a realistic analysis of the pharmacokinetic-pharmacodynamic relationship of AL in patients who receive AL for cholangiocarcinoma treatment and bacterial infections.
Financial support and sponsorship
This work was supported by the Thailand Science Research and Innovation Fundamental Fund, National Research Council of Thailand, Research and Innovation of Thailand (Frontier Research Seed Fund grant number TUFF20/2564), and Thammasat University (Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma). The authors have no relevant affiliations.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Xiao PG. Modern Chinese Materia Medica. Vol. 1. Beijing, China: Science Press; 2002.
Chayamarit KK. Thai Medicinal Plants, Department of Forestry. Bangkok, Thailand: Bangkok Printing Press; 1995.
Kitajima J, Kamoshita A, Ishikawa T, Takano A, Fukuda T, Isoda S, et al
. Glycosides of Atractylodes lancea
. Chem Pharm Bull (Tokyo) 2003;51:673-8.
Koonrungsesomboon N, Na-Bangchang K, Karbwang J. Therapeutic potential and pharmacological activities of Atractylodes lancea
(Thunb.) DC. Asian Pac J Trop Med 2014;7:421-8.
Kishida Y, Miki H, Nishii T, Inoue T, Nishida S, Yoshikawa H, et al
. Therapeutic effects of Saireito (TJ-114), a traditional Japanese herbal medicine, on postoperative edema and inflammation after total hip arthroplasty. Phytomedicine 2007;14:581-6.
Na-Bangchang K, Plengsuriyakarn T, Karbwang J. Research and development of Atractylodes lancea
(Thunb) DC. As a promising candidate for cholangiocarcinoma chemotherapeutics. Evid Based Complement Alternat Med 2017;2017:5929234.
Na-Bangchang K, Kulma I, Plengsuriyakarn T, Tharavanij T, Kotawng K, Chemung A, et al
. Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea
. J Tradit Complement Med 2021;11:343-55.
Li N, Deng C, Li Y, Ye H, Zhang X. Gas chromatography-mass spectrometry following microwave distillation and headspace solid-phase microextraction for fast analysis of essential oil in dry traditional Chinese medicine. J Chromatogr A 2006;1133:29-34.
Jun X, Fu P, Lei Y, Cheng P. Pharmacological effects of medicinal components of Atractylodes lancea
(Thunb.) DC. Chin Med 2018;13:59.
Chen LG, Jan YS, Tsai PW, Norimoto H, Michihara S, Murayama C, et al
. Anti-inflammatory and antinociceptive constituents of Atractylodes
Japonica Koidzumi. J Agric Food Chem 2016;64:2254-62.
Kim JH, Doh EJ, Lee G. Evaluation of medicinal categorization of Atractylodes
Japonica Koidz. By using internal transcribed spacer sequencing analysis and HPLC fingerprinting combined with statistical tools. Evid Based Complement Alternat Med 2016;2016:2926819.
Xia YG, Yang BY, Wang QH, Liang J, Wang D, Kuang HX. Species classification and quality assessment of Cangzhu
) by high-performance liquid chromatography and chemometric methods. J Anal Methods Chem 2013;2013:497532.
Wang F, Ouyang Z, Guo LP, Zhao M, Peng HS, Liao JL, et al
. Comprehensive chemical pattern recognition of Atractylodis rhizoma
. Zhongguo Zhong Yao Za Zhi 2014;39:2536-41.
Yan Y, Zhao H, Zou LS, Liu XH, Chai C, Wang SN, et al
. Chemical constituents of eucommiae Cortex by LC-triple TOF MS/MS. J Chin Mass Spec Soc 2017;1:146-56.
Zhang Y, Bo C, Fan Y, An R, Chen L, Zhang Y, et al
. Qualitative and quantitative determination of Atractylodes
rhizome using ultra-performance liquid chromatography coupled with linear ion trap-orbitrap mass spectrometry with data-dependent processing. Biomed Chromatogr 2019;33:e4443.
Karmakar A, Dua P, Ghosh C. Biochemical and molecular analysis of staphylococcus aureus
clinical isolates from hospitalized patients. Can J Infect Dis Med Microbiol 2016;2016:9041636.
CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard, 9th
ed. CLSI document M07-A9. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2012.
Xiao-Wen C, Chen-Xi X, Yu-Qiang L, Cai Q. Determination and pharmacokinetic comparisons of Atractylodin
after oral administration of crude and processed Atractylodis
rhizoma. Pharmacogn Mag 2016;12:80-3.
FDA. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services: Food and Drug Administration; 2001.
Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J 2007;9:E117-22.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]